Stockreport

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc - Ordinary Shares  (PRTA) 
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.prothena.com
PDF Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Coramitug is being evaluated by Novo Nordisk [Read more]